| 
																	
																	
																		 Connection
 
																		  Bradley  Corr  to  Drug Resistance, Neoplasm 
																		
																	 
																		 This is a "connection" page, showing publications  Bradley  Corr  has written about  Drug Resistance, Neoplasm.  
																		
																	 
																			
																					
	
						
				
		
			
			
			|  | 
				
					|  | Connection Strength |  |  
					|  |   |  |  
					|  | 0.346 |  |  |  |  
		
		
			
				Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.	
				
				
					Score: 0.163
				
				Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2015 Nov; 25(9):1565-73.	
				
				
					Score: 0.085
				
				Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu?n A, G?lvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio P?rez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar; 36(3):321-330.	
				
				
					Score: 0.040
				
				McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. Int J Mol Sci. 2020 Jun 16; 21(12).	
				
				
					Score: 0.029
				
				Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.	
				
				
					Score: 0.029
				 | 
																	
																		
																			
																					    Connection Strength   
  The connection strength for concepts is the sum of the scores for each matching publication.  
 Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
 |